Key facts
- This page summarizes Michael W. Kalb's Form 3 filing for IMPEL PHARMACEUTICALS INC.
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 May 2023, 16:22.
Michael W. Kalb - 10 May 2023 Form 3 Insider Report for IMPEL PHARMACEUTICALS INC
- SEC form
- 3
- Accepted by SEC
- 12 May 2023, 16:22:23 UTC
- Prior SEC filing
- 24 Feb 2023
- Next SEC filing
- 03 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adrian Adams as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael W. Kalb filed Form 3 for IMPEL PHARMACEUTICALS INC on 12 May 2023.
Change
- Previous filing in this sequence was filed on 24 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMPL
holding
No securities beneficially held.
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 10 May 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Exhibit 24.1 - Power of Attorney